Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Free Cash Flow: 2010-2024

Historic Free Cash Flow for Whitehawk Therapeutics (WHWK) over the last 14 years, with Dec 2024 value amounting to -$61.2 million.

  • Whitehawk Therapeutics' Free Cash Flow rose 3.13% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$96.0 million, marking a year-over-year decrease of 70.12%. This contributed to the annual value of -$61.2 million for FY2024, which is 3.82% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its Free Cash Flow stood at -$61.2 million for FY2024, which was up 3.82% from -$63.6 million recorded in FY2023.
  • In the past 5 years, Whitehawk Therapeutics' Free Cash Flow registered a high of -$12.7 million during FY2020, and its lowest value of -$63.6 million during FY2023.
  • Moreover, its 3-year median value for Free Cash Flow was -$61.2 million (2024), whereas its average is -$58.3 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first spiked by 47.20% in 2020, then slumped by 122.90% in 2022.
  • Over the past 5 years, Whitehawk Therapeutics' Free Cash Flow (Yearly) stood at -$12.7 million in 2020, then tumbled by 76.64% to -$22.5 million in 2021, then tumbled by 122.90% to -$50.1 million in 2022, then fell by 27.06% to -$63.6 million in 2023, then climbed by 3.82% to -$61.2 million in 2024.